Submit Manuscript  

Article Details

Recent Advances in the Design of Cathepsin S Inhibitors

[ Vol. 10 , Issue. 7 ]


John J. M. Wiener, Siquan Sun and Robin L. Thurmond   Pages 717 - 732 ( 16 )


Cathepsin S has been of increasing interest as a target of medicinal chemistry efforts given its role in modulating antigen-presentation by major histocompatibility class II (MHC II) molecules as well as its involvement in extracellular proteolytic activities. Inhibition of the cathepsin S enzyme reduces degradation of the invariant chain, a crucial chaperon which also blocks peptide-binding by MHC II molecules, thereby decreasing antigen presentation to CD4+ T-cells. Extracellular cathepsin S may also be involved in angiogenesis and initiation and/or maintenance of neuropathic pain by cleavage of the membrane-bound chemokine fractalkine (CX3CL1). Cathepsin S inhibitors have thus been suggested to hold potential as therapeutics for a variety of diseases. The initial development of cathepsin S inhibitors targeted irreversible, covalent inhibitors, but more recently the focus has been on reversible inhibitors, representing both covalent modifiers of the enzyme and, of late, noncovalent inhibitors. This review details advances in cathepsin S inhibitor design as reported in the primary literature since 2006, focusing especially on structure-activity relationships of the various covalent and noncovalent inhibitor series.


Cathepsin S, inhibitor, antigen presentation, protease, autoimmune disease, inflammation, immunomodulator, covalent binding, noncovalent binding


Johnson&Johnson Pharmaceutical Research&Development, L.L.C., 3210 Merryfield Row, San Diego, CA 92121.

Read Full-Text article